251 related articles for article (PubMed ID: 6218559)
21. The in-vivo antibacterial activity of ceftazidime (Gr 20263)--a comparison with other new beta-lactam antibiotics and gentamicin.
Acred P; Ryan DM; Sowa MA; Watts CM
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():247-55. PubMed ID: 19802994
[TBL] [Abstract][Full Text] [Related]
22. In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance.
Brown JE; Del Bene VE; Collins CD
Antimicrob Agents Chemother; 1981 Feb; 19(2):248-52. PubMed ID: 6214986
[TBL] [Abstract][Full Text] [Related]
23. Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli.
Kurtz TO; Winston DJ; Hindler JA; Young LS; Hewitt WL; Martin WJ
Antimicrob Agents Chemother; 1980 Oct; 18(4):645-8. PubMed ID: 6255864
[TBL] [Abstract][Full Text] [Related]
24. Moxalactam: the first of a new class of beta-lactam antibiotics.
Webber JA; Yoshida T
Rev Infect Dis; 1982; 4 Suppl():S496-500. PubMed ID: 6218558
[TBL] [Abstract][Full Text] [Related]
25. [Comparison of sensitivity patterns of bacteria isolated from clinical materials to the 2d generation cephamycins and cephalosporins and clinical application of these antibiotics].
Matsuo K; Uete T
Jpn J Antibiot; 1983 Jul; 36(7):1621-37. PubMed ID: 6317908
[TBL] [Abstract][Full Text] [Related]
26. Comparison of moxalactam (LY127935) and cefotaxime against anaerobic bacteria.
Jorgensen JH; Crawford SA; Alexander GA
Antimicrob Agents Chemother; 1980 May; 17(5):901-4. PubMed ID: 6249198
[TBL] [Abstract][Full Text] [Related]
27. Comparison of in vitro activity of moxalactam (LY127935) with cefazolin, amikacin, tobramycin, carbenicillin, piperacillin, and ticarcillin against 420 blood culture isolates.
Reimer LG; Mirrett S; Reller LB
Antimicrob Agents Chemother; 1980 Mar; 17(3):412-6. PubMed ID: 6448577
[TBL] [Abstract][Full Text] [Related]
28. Moxalactam therapy for bacterial infections.
Winston DJ; Busuttil RW; Kurtz TO; Young LS
Arch Intern Med; 1981 Nov; 141(12):1607-12. PubMed ID: 6458253
[TBL] [Abstract][Full Text] [Related]
29. Susceptibility of moxalactam to beta-lactamase.
Richmond MH
Rev Infect Dis; 1982; 4 Suppl():S522-6. PubMed ID: 6218561
[TBL] [Abstract][Full Text] [Related]
30. Moxalactam: an oxa-beta-lactam antibiotic that inactivates beta-lactamases.
Labia R
Rev Infect Dis; 1982; 4 Suppl():S529-35. PubMed ID: 6218563
[TBL] [Abstract][Full Text] [Related]
31. Antimicrobial activity, beta-lactamase stability and beta-lactamase inhibition of cefotetan and other 7-alpha-methoxy beta-lactam antimicrobials.
Jones RN; Wilson HW
Diagn Microbiol Infect Dis; 1983 Mar; 1(1):71-83. PubMed ID: 6323095
[TBL] [Abstract][Full Text] [Related]
32. In vitro comparative activity of moxalactam, GR 20263, and N-formimidoyl thienamycin to other beta-lactam antibiotics and tobramycin against enterobacteriaceae and staphylococci.
Cynamon MH; Granato PA
Chemotherapy; 1982; 28(3):204-8. PubMed ID: 6212205
[TBL] [Abstract][Full Text] [Related]
33. In vitro activity of moxalactam against anaerobic bacteria.
Gilchrist MJ; Washington JA
Rev Infect Dis; 1982; 4 Suppl():S511-5. PubMed ID: 6218560
[TBL] [Abstract][Full Text] [Related]
34. In vitro evaluation of LY127935, a new beta-lactam antibiotic with broad-spectrum activity.
Clarke AM; Zemcov SJ
J Antimicrob Chemother; 1980 Jul; 6(4):495-8. PubMed ID: 6448833
[No Abstract] [Full Text] [Related]
35. Study of the in vitro activity of new cephalosporins on strains of Neisseria gonorrhoeae of the Toulouse region.
Prère MF; Lefèvre JC; Lareng MB
Chemotherapy; 1981; 27 Suppl 1():15-8. PubMed ID: 6265158
[TBL] [Abstract][Full Text] [Related]
36. [Comparative study of ceftriaxone, cefotaxime and moxalactam against 150 Gram negative strains (author's transl)].
Nasnas R; Gutmann L; Kitzis MD; Goldstein F; Acar JF
Pathol Biol (Paris); 1982 Jun; 30(6):341-4. PubMed ID: 6287385
[TBL] [Abstract][Full Text] [Related]
37. Aminoglycoside-resistant gram-negative bacilli in a community hospital: comparative in vitro activity of cefotaxime, moxalactam, cefoperazone, and piperacillin.
Magnussen CR; Sammartino MT; Ernest KD
Antimicrob Agents Chemother; 1982 Jul; 22(1):154-6. PubMed ID: 6289736
[TBL] [Abstract][Full Text] [Related]
38. [Bacteriological investigations with a new Semisynthetic oxy-beta-lactam antibiotic LY 127935 (AUTHOR'S TRANSL)].
Malottke R
Infection; 1980; 8(1):43-5. PubMed ID: 6445339
[TBL] [Abstract][Full Text] [Related]
39. Clinical evaluation of a new broad-spectrum oxa-beta-lactam antibiotic, moxalactam, in neonates and infants.
Schaad UB; McCracken GH; Threlkeld N; Thomas ML
J Pediatr; 1981 Jan; 98(1):129-36. PubMed ID: 6450277
[TBL] [Abstract][Full Text] [Related]
40. N-Formimidoyl thienamycin (MK0787): in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.
Hanslo D; King A; Shannon K; Warren C; Phillips I
J Antimicrob Chemother; 1981 Jun; 7(6):607-17. PubMed ID: 6265426
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
